Cytek Biosciences Inc (CTKB) News

Form 8-K - Current report

Cytek Biosciences Reports First Quarter 2024 Financial Results

FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”...

Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe

FREMONT, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell...

Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024

FREMONT, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell...

Cytek® Biosciences Names William McCombe Chief Financial Officer

Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions

FREMONT, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell...

Form 8-K - Current report

Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities